[go: up one dir, main page]

GB0418388D0 - Cell therapy - Google Patents

Cell therapy

Info

Publication number
GB0418388D0
GB0418388D0 GBGB0418388.5A GB0418388A GB0418388D0 GB 0418388 D0 GB0418388 D0 GB 0418388D0 GB 0418388 A GB0418388 A GB 0418388A GB 0418388 D0 GB0418388 D0 GB 0418388D0
Authority
GB
United Kingdom
Prior art keywords
cell therapy
treatment
methods
relates
exo1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0418388.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newcastle University of Upon Tyne
Original Assignee
Newcastle University of Upon Tyne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newcastle University of Upon Tyne filed Critical Newcastle University of Upon Tyne
Priority to GBGB0418388.5A priority Critical patent/GB0418388D0/en
Publication of GB0418388D0 publication Critical patent/GB0418388D0/en
Priority to PCT/GB2005/003211 priority patent/WO2006018632A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/11—Exodeoxyribonucleases producing 5'-phosphomonoesters (3.1.11)
    • C12Y301/11001—Exodeoxyribonuclease I (3.1.11.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to cell therapy, and in particular to the use of exol gene and the EXO1 enzyme in medicine, and to the uses thereof in treatment and therapy of various diseases. In particular, the invention relates to the treatment or prevention of cancer and/or aging, and to methods of carrying out such methods, including recombinant constructs encoding EXO1.
GBGB0418388.5A 2004-08-18 2004-08-18 Cell therapy Ceased GB0418388D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0418388.5A GB0418388D0 (en) 2004-08-18 2004-08-18 Cell therapy
PCT/GB2005/003211 WO2006018632A2 (en) 2004-08-18 2005-08-17 Cell therapy with exo 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0418388.5A GB0418388D0 (en) 2004-08-18 2004-08-18 Cell therapy

Publications (1)

Publication Number Publication Date
GB0418388D0 true GB0418388D0 (en) 2004-09-22

Family

ID=33042231

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0418388.5A Ceased GB0418388D0 (en) 2004-08-18 2004-08-18 Cell therapy

Country Status (2)

Country Link
GB (1) GB0418388D0 (en)
WO (1) WO2006018632A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157747A1 (en) * 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
EP2077335A1 (en) * 2007-12-22 2009-07-08 Universitätsklinikum Schleswig-Holstein EXO1 promoter polymorphism associated with exceptional life expectancy in humans
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US20140335074A1 (en) 2011-12-13 2014-11-13 Buck Institute For Research On Aging Methods for improving medical therapies
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
AR096673A1 (en) * 2013-06-19 2016-01-27 Buck Inst For Res On Aging METHODS TO INCREASE THE EFFECTIVENESS OF MEDICAL THERAPIES
IL311537A (en) 2014-01-28 2024-05-01 Mayo Found Medical Education & Res Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
WO2017223107A1 (en) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6418294A (en) * 1993-03-30 1994-10-24 United States Biochemical Corporation Use of exonuclease in dna sequencing
US6379940B2 (en) * 2000-03-21 2002-04-30 Usb Corporation Stable composition comprising a nuclease and a phosphatase

Also Published As

Publication number Publication date
WO2006018632A3 (en) 2006-05-04
WO2006018632A2 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
UA89957C2 (en) Chimeric adenoviruses for use in cancer treatment
GB0418388D0 (en) Cell therapy
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
RS20150135A1 (en) Treatment with anti-vegf antibodies
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
WO2005030121A3 (en) Compounds, compositions and methods
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2005063819A3 (en) Human binding molecule against cd1a
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
MXPA05012421A (en) Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents.
MX2009005849A (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna.
DE602005012276D1 (en) USE OF PROBIOTIC BACTERIA FOR THE PREPARATION OF TOPICAL COMPOSITIONS FOR THE PROTECTION OF THE SKIN
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
NZ579050A (en) Treatment and prevention of neurodegenerative diseases using gene therapy
WO2006108474A3 (en) Use of a galectin-1-trageted rnai-based approach for the treatment of cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
TW200716749A (en) Interferon-beta gene therapy using an improved, regulated expression system
WO2006103494A3 (en) Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
MX2012000541A (en) Therapeutic peptides, polypeptides ans nucleic acid sequences.
WO2006107751A3 (en) Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)